Prosecution Insights
Last updated: November 12, 2026
Application No. 18/725,231

L-N-isobutyryl cysteine (L-NIBC)-bound gold cluster Au18(L-NIBC)14, compositions and applications thereof

Non-Final OA §102
Filed
Jun 28, 2024
Priority
Jan 20, 2022 — nonprovisional of PCTCN2022073051
Examiner
INAM, SAHAR
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shenzhen Profound View Pharmaceutical Technology Co. Ltd.
OA Round
1 (Non-Final)
100%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 100% — above average
100%
Career Allowance Rate
2 granted / 2 resolved
+40.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
25 currently pending
Career history
27
Total Applications
across all art units

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicants’ election without traverse of Group I (i.e., claims 1 and 9-11) in the reply filed on 9/23/2026 is acknowledged. Applicants’ amendment of claim 1 is acknowledged. Applicant’s cancellation of claims 5-8 and 12-24 is acknowledged. Since the applicant elected group I (i.e., claims 1 and 9-11), therefore, based on that election, claims 2, 3 and 4 are withdrawn as being drawn to a non-elected group. With regards to the applicant’s remarks filed 9/23/2026, the examiner acknowledges the referenced specification paragraph and applicant’s arguments concerning the alleged absence of a teaching of “Au₁₈(L-NIBC)₁₄” in WO 2021/184762 A1 (WUHAN VAST CONDUCT SCIENCE FOUND CO LTD [CN]) 23 September 2021 in view of WO 2021/226736 A1 (SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECH CO LTD [CN]) 18 November 2021, disclosed in the IDS filed 06/28/2024. However, the examiner respectfully maintains the restriction in light of Gautier et al. (“Cyrille Gautier, Thomas Bürgi; Chiral Inversion of Gold Nanoparticles.” Journal American Chemical Society 4 June 2008; 130 (22): 7077–7084.) that explicitly teaches the instant composition and explained in detail below (Claim Rejections - 35 USC § 102). Accordingly, a skilled artisan seeking to obtain a particular L-NIBC-bound gold cluster would have been motivated to investigate variations of the disclosed preparation conditions, isolate the resulting compounds and characterize their compositions using appropriate analytical techniques. Furthermore, one of ordinary skill in the art would have been motivated to do so due to the existence of known synthesis methods and ability to vary reaction parameters that support the feasibility of experimentation. Thus, Gautier’s particular claimed molecular formula would have been an expected result of routine experimentation of Wuhan and Shenzhen disclosed L-N-isobutyryl cysteine (L-NIBC)-bound gold cluster of formula (L-NIBC-AuCs). The applicant also refers to corresponding Australian, European and Japanese applications that were granted. Those grants may be useful context, but they do not independently establish that the U.S. claims are patentable or unpatentable and are not binding on the USPTO. The underlying claim scope, prior art record and examination reasoning must be assessed in the relevant jurisdiction. Status of Claims Claims 1-4 and 9-11 are pending. The preliminary amendment was filed on 6/28/2024, wherein the applicant amended claims 2-4 and 9-11, and canceled claims 5-8 and 12-24. There are no new claims. Claims 1 and 9-11 are under consideration in the instant office action. Information Disclosure Statement The information disclosure statement (IDS) submitted on 6/28/2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 9-11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Gautier et al. (“Cyrille Gautier, Thomas Bürgi; Chiral Inversion of Gold Nanoparticles.” Journal American Chemical Society 4 June 2008; 130(22): 7077–7084.) herein referred to as Gautier. Regarding claims 1 and 9-11, Gautier teaches the instant composition as the first set of experiments was performed with the gold NPs covered by either N-isobutyryl-L-cysteine (NILC) or N-isobutyryl-D-cysteine (NIDC, Chart 1 on page 7079). These particles were separated by polyacrylamide gel electrophoresis (PAGE) into eight well-defined compounds, i.e., compounds with a precise number of gold atoms and ligands (Para. 1, Lines 1-4, Results and Discussion, Effect of Dissolved Oxygen on Core-Size Retention during the Thiolate-for-Thiolate Ligand Exchange on page 7078). Gautier explicitly teaches Au10(NIC)10, Au15(NIC)13, and Au18(NIC)14 similar to the compound of claim 1 (Para. 1, Line 10, Results and Discussion, Effect of Dissolved Oxygen on Core-Size Retention during the Thiolate-for-Thiolate Ligand Exchange on page 7078). Gautier also discloses that further experiments were performed under an inert atmosphere with the species 2 and 3 of the gold NPs protected with NILC, which correspond, respectively, to Au15(NILC)13 and Au18(NILC)14. These compounds can be isolated again after 1 h of reaction with the ligand of opposite absolute configuration by UF and PAGE in order to eliminate the small contribution of NPs of different sizes (Para. 1, Lines 1-5, Inversion of the Absolute Configuration of the Ligands). Gautier teaches the thiolate-for-thiolate ligand exchange was performed on well-defined gold nanoparticles under an inert atmosphere without any modification of the core size (Abstract). Gautier teaches the following chemical structures of the thiols used (Chart 1, pg. 7079) PNG media_image1.png 522 530 media_image1.png Greyscale The scope of Gautier’s compounds overlaps with the L-N-isobutyryl cysteine (L-NIBC)-bound gold cluster molecule composition of the instant claims and includes the specific gold cluster molecule recited in Applicant’s claim 1, i.e., Au18(L-NIC)14, which is the same compound that Applicant refers to as Au18(L-NIBC)14. With regards to claims 10 and 11, the examiner notes the phrases “is used as a component in a mixture of gold cluster molecules in the composition, the L-NIBC-bound gold cluster molecule Au₁₈(L-NIBC)₁₄ has a chromatographic content of at least 7% in the mixture” and “wherein the disease is one selected from the group consisting of multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, Type 2 diabetes, Parkinson's disease (PD), and glaucoma”. This claim language is not a structural or functional limitation but a statement of intended use. Under MPEP 1504.04, such language is generally given no patentable weight and cannot be used to distinguish prior art or support non-obviousness Based on the foregoing reasons, the instant claims are deemed anticipated over the cited art. Conclusion Claims 1 and 9-11 are rejected. Claims 2-4 are withdrawn. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAHAR INAM whose telephone number is (571)272-0821. The examiner can normally be reached 7:30 am-5:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAHAR INAM/ Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Jun 28, 2024
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780813
HSD17B13 INHIBITORS AND/OR DEGRADERS
3y 0m to grant Granted Nov 03, 2026
Patent 12760000
PYRIDAZINE DERIVATIVES AS MODULATORS OF NLRP3 INFLAMMASOME AND RELATED METHODS
2y 3m to grant Granted Oct 13, 2026
Patent 12753162
METHOD FOR PRODUCING 2-HETEROARYLPYRIDINE COMPOUND
2y 6m to grant Granted Oct 06, 2026
Patent 12734164
PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY
2y 11m to grant Granted Sep 15, 2026
Patent 12709624
MODULAR SYNTHESIS OF 1,2-AZABORINES VIA RING-OPENING BN-ISOSTERE BENZANNULATION
2y 10m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
100%
Grant Probability
99%
With Interview (+0.0%)
Low
PTA Risk
Based on 2 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month